Research location
Botany
New South Wales, Australia
Advertisement
Research activity in Botany
New South Wales, AustraliaCureCurrent currently publishes aggregate city-level research activity for this location: 16 trials and 16 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Botany
16 linked trials · page 1 of 1Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235 · 2026-07-23 · 1 site observation
RECRUITING
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07509307 · 2026-04-20 · 1 site observation
RECRUITING
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07481630 · 2026-04-13 · 1 site observation
RECRUITING
Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate AsthmaNCT07245368 · 2025-11-04 · 1 site observation
RECRUITING
Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients.NCT07234864 · 2025-11-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 · 2025-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic ParticipantsNCT06648031 · 2024-12-04 · 1 site observation
COMPLETED
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With AsthmaNCT06261957 · 2024-05-31 · 1 site observation
COMPLETED
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 · 2023-08-01 · 1 site observation
COMPLETED
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 · 2023-07-11 · 1 site observation
COMPLETED
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 · 2023-07-10 · 1 site observation
COMPLETED
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620 · 2023-06-05 · 1 site observation
COMPLETED
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 · 2023-05-30 · 1 site observation
COMPLETED
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to MethotrexateNCT04909801 · 2021-09-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)NCT04888585 · 2021-06-23 · 1 site observation
TERMINATED
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisNCT03915964 · 2019-04-25 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.